Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

from WolverHeme Happy Hour · host Bernard Marini, Anthony Perissinotti, et al.

In this episode, Bernie and Anthony are joined by two special guest expert hematologists: Dr. David Russler-Germain Dr. Tycel Phillips We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired? Stay tuned to find out!

Episode metadata supplied by the publisher feed · Published Nov 8, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

0:00 48:07

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of WolverHeme Happy Hour?

This episode is 48 minutes long.

When was this WolverHeme Happy Hour episode published?

This episode was published on November 8, 2024.

Can I download this WolverHeme Happy Hour episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!